Hypera 과거 수익 실적
과거 기준 확인 2/6
Hypera has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 20.6% per year. Hypera's return on equity is 14.1%, and it has net margins of 21.2%.
주요 정보
8.9%
수익 성장률
8.8%
EPS 성장률
Pharmaceuticals 산업 성장 | 12.4% |
매출 성장률 | 20.6% |
자기자본 수익률 | 14.1% |
순이익 | 21.2% |
다음 실적 업데이트 | 13 Nov 2024 |
최근 과거 실적 업데이트
Recent updates
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
Oct 03We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Jul 13Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
Jun 20Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 16Is Hypera (BVMF:HYPE3) A Risky Investment?
Feb 21Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Jan 09Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
Dec 22Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Nov 02Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Aug 27Is Hypera (BVMF:HYPE3) A Risky Investment?
Jul 21We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Apr 15With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
Feb 19We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
Jan 03Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
Oct 11Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Jul 19Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Jun 28Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Apr 14I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Mar 25Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Mar 04수익 및 비용 분석
Hypera 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 8,001 | 1,693 | 2,507 | 0 |
31 Mar 24 | 8,043 | 1,704 | 2,511 | 0 |
31 Dec 23 | 7,915 | 1,649 | 2,521 | 0 |
30 Sep 23 | 8,189 | 1,772 | 2,531 | 0 |
30 Jun 23 | 8,086 | 1,741 | 2,492 | 0 |
31 Mar 23 | 7,751 | 1,694 | 2,375 | 0 |
31 Dec 22 | 7,546 | 1,705 | 2,299 | 0 |
30 Sep 22 | 7,051 | 1,640 | 2,121 | 0 |
30 Jun 22 | 6,648 | 1,636 | 2,017 | 0 |
31 Mar 22 | 6,260 | 1,660 | 1,955 | 0 |
31 Dec 21 | 5,937 | 1,618 | 1,895 | 0 |
30 Sep 21 | 5,446 | 1,577 | 1,872 | 0 |
30 Jun 21 | 4,902 | 1,462 | 1,756 | 0 |
31 Mar 21 | 4,445 | 1,382 | 1,626 | 0 |
31 Dec 20 | 4,089 | 1,322 | 1,564 | 0 |
30 Sep 20 | 3,883 | 1,243 | 1,538 | 0 |
30 Jun 20 | 3,803 | 1,165 | 1,605 | 0 |
31 Mar 20 | 3,726 | 1,106 | 1,635 | 0 |
31 Dec 19 | 3,295 | 1,189 | 1,611 | 0 |
30 Sep 19 | 3,294 | 1,252 | 1,558 | 0 |
30 Jun 19 | 3,233 | 1,225 | 1,508 | 0 |
31 Mar 19 | 3,180 | 1,164 | 1,469 | 0 |
31 Dec 18 | 3,724 | 1,135 | 1,481 | 0 |
30 Sep 18 | 3,789 | 1,288 | 1,508 | 0 |
30 Jun 18 | 3,716 | 1,251 | 1,477 | 0 |
31 Mar 18 | 3,613 | 1,200 | 1,430 | 0 |
31 Dec 17 | 3,500 | 1,111 | 1,410 | 0 |
30 Sep 17 | 3,291 | 819 | 1,397 | 0 |
30 Jun 17 | 3,226 | 795 | 1,380 | 0 |
31 Mar 17 | 3,216 | 743 | 1,394 | 0 |
31 Dec 16 | 3,228 | 647 | 1,372 | 0 |
30 Sep 16 | 3,202 | 557 | 1,360 | 0 |
30 Jun 16 | 3,129 | 432 | 1,339 | 0 |
31 Mar 16 | 3,046 | 349 | 1,323 | 0 |
31 Dec 15 | 2,957 | 345 | 1,307 | 0 |
30 Sep 15 | 1,589 | 263 | 774 | 0 |
30 Jun 15 | 2,039 | 326 | 944 | 0 |
31 Mar 15 | 2,447 | 360 | 1,095 | 0 |
31 Dec 14 | 2,768 | 338 | 1,245 | 0 |
30 Sep 14 | 4,498 | 400 | 1,913 | 0 |
30 Jun 14 | 4,423 | 357 | 1,863 | 0 |
31 Mar 14 | 4,359 | 249 | 1,851 | 0 |
31 Dec 13 | 4,259 | 259 | 1,804 | 0 |
양질의 수익: HYPE3 has high quality earnings.
이익 마진 증가: HYPE3's current net profit margins (21.2%) are lower than last year (21.5%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: HYPE3's earnings have grown by 8.9% per year over the past 5 years.
성장 가속화: HYPE3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: HYPE3 had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.3%).
자기자본 수익률
높은 ROE: HYPE3's Return on Equity (14.1%) is considered low.